InvestorsObserver is giving Cyclacel Pharmaceuticals Inc (CYCC) an Analyst Rating Rank of 78, meaning CYCC is ranked higher by analysts than 78% of stocks. The average price target for CYCC is $21.333 and analyst’s rate the stock as a Strong Buy
Why are Analyst Ratings Important?
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With Cyclacel Pharmaceuticals Inc Stock Today?
Cyclacel Pharmaceuticals Inc (CYCC) stock is trading at $8.69 as of 1:25 PM on Wednesday, Feb 17, a loss of -$0.45, or -4.92% from the previous closing price of $9.14. The stock has traded between $8.51 and $9.05 so far today. Volume today is light. So far 389,922 shares have traded compared to average volume of 1,013,189 shares.
Click Here to get the full report on Cyclacel Pharmaceuticals Inc (CYCC) Stock.
